Title:
ＴＰ５３のヘミ接合性喪失を保有するがんを処置する方法
Document Type and Number:
Japanese Patent JP7090933
Kind Code:
B2
Abstract:
Provided herein are methods of treating a patient having a cancer that exhibits (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) expression level. The methods comprise administering a therapeutically effective amount of a POLR2A inhibitor (e.g., a nucleic acid that inhibits the expression of a POLR2A protein, an amatoxin, alpha-amanitin, or alpha-amanitin conjugated to a cell targeting moiety, such as an EpCAM antibody) to a patient having or determined to have (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) level.
Inventors:
Shonbin Lou
Yunfariu
Yunfariu
Application Number:
JP2020180195A
Publication Date:
June 27, 2022
Filing Date:
October 28, 2020
Export Citation:
Assignee:
BOARD OF REGENTS,THE UNIVERSITY OF TEXAS SYSTEM
International Classes:
A61K47/64; A61K31/282; A61K31/4745; A61K31/513; A61K38/08; A61K39/395; A61P35/00; A61P35/04; A61P43/00
Domestic Patent References:
| JP2012523383A | ||||
| JP2011528680A |
Other References:
MOOK, ORF. et al.,Cancer Gene Therapy,2009年01月,Vol.16, No.6,pp.532-538.
FLUITER, K. et al.,Cancer Research,2002年,Vol.62, No.7,pp.2024-2028.,インターネット:
FLUITER, K. et al.,Cancer Research,2002年,Vol.62, No.7,pp.2024-2028.,インターネット:
Attorney, Agent or Firm:
Shusaku Yamamoto
Morishita Natsuki
Morishita Natsuki